Emerging therapies for the treatment of sepsis

Current Opinion in Anaesthesiology

Volumn 28, Issue 4, 2015, Pages 411-416

  Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

heterogeneity; immunomodulation; immunostimulation; sepsis

Indexed keywords

ALKALINE PHOSPHATASE; BETA INTERFERON; CORTICOSTEROID; IMMUNOGLOBULIN; SELEPRESSIN; THROMBOMODULIN; VASOPRESSIN DERIVATIVE;

CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; EXTRACORPOREAL THERAPY; HUMAN; IMMUNOSTIMULATION; IMMUNOTHERAPY; MULTICENTER STUDY (TOPIC); PHARMACONUTRIENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; THERAPY; DIET THERAPY; EXTRACORPOREAL CIRCULATION; IMMUNOLOGY;

ALKALINE PHOSPHATASE; EXTRACORPOREAL CIRCULATION; HUMANS; IMMUNOGLOBULINS; INTERFERON-BETA; NUTRITION THERAPY; SEPSIS; THROMBOMODULIN; VASOPRESSINS;

EID: 84937836655     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0000000000000210     Document Type: Review

References (53)

1. Vincent JL. We should abandon randomized controlled trials in the intensive care unit. Crit Care Med 2010; 38:S534-S538.
2. Vincent JL, Opal S, Marshall JC, et al. Sepsis definitions: time for change. Lancet 2013; 381:774-775.
3. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655.
4. Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014; 311:1308-1316.
5. Rhee C, Murphy MV, Li L, et al. Comparison of trends in sepsis incidence and coding using administrative claims versus objective clinical data. Clin Infect Dis 2015; 60:88-95. were used.
6. Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013; 309:1154-1162.
7. Vincent JL, Marshall J, Dellinger RP, et al. Talactoferrin in sepsis: Results from the phase II/III OASIS trial. Crit Care Med 2015. (in press).
8. Bernard GR, Francois B, Mira JP, et al. Evaluating the efficacy and safety of two doses of the polyclonal antitumor necrosis factor-alpha fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study. Crit Care Med 2014; 42:504-511.
9. Semeraro N, Ammollo CT, Semeraro F, et al. Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. Mediterr J Hematol Infect Dis 2010; 2:e2010024.
10. Afshari A, Wetterslev J, Brok J, et al. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 2007; 335:1248-1251.
11. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290:238-247.
12. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
13. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064.
14. Kalil AC, LaRosa SP. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis 2012; 12:678-686.
15. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109:3161-3172.
16. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115:1267-1274.
17. Vincent JL, Ramesh MK, Ernest D, et al. A randomized, double-blind, placebocontrolled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013; 41:2069-2079.
18. Shankar-Hari M, Spencer J, Sewell WA, et al. Bench-to-bedside review: immunoglobulin therapy for sepsis-biological plausibility from a critical care perspective. Crit Care 2012; 16:206.
19. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007; 35:2686-2692.
20. Almansa R, Tamayo E, Andaluz-Ojeda D, et al. The original sins of clinical trials with intravenous immunoglobulins in sepsis. Crit Care 2015; 19:793.
21. Kreymann KG, De Heer G, Nierhaus A, et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007; 35:2677-2685.
22. Cavazzuti I, Serafini G, Busani S, et al. Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock. Intensive Care Med 2014; 40:1888-1896.
23. Taccone FS, Stordeur P, De Backer D, et al. Gamma-globulin levels in patients with community-acquired septic shock. Shock 2009; 32:379-385.
24. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39:165-228.
25. Jardine D, Emond M, Meert KL, et al. A single nucleotide polymorphism in the corticotropin receptor gene is associated with a blunted cortisol response during pediatric critical illness. Pediatr Crit Care Med 2014; 15:698-705.
26. Wong HR, Cvijanovich NZ, Anas N, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med 2015; 191:309-315.
27. Boonen E, Vervenne H, Meersseman P, et al. Reduced cortisol metabolism during critical illness. N Engl J Med 2013; 368:1477-1488.
28. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:1752-1758.
29. Luckner G, Dunser MW, Jochberger S, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005; 33:2659-2666.
30. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107:2313-2319.
31. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887.
32. Bucher M, Hobbhahn J, Taeger K, et al. Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am J Physiol Regul Integr Comp Physiol 2002; 282:R979-R984.
33. Schmidt C, Hocherl K, Kurt B, et al. Role of nuclear factor-kappaB-dependent induction of cytokines in the regulation of vasopressin V1A-receptors during cecal ligation and puncture-induced circulatory failure. Crit Care Med 2008; 36:2363-2372.
34. Maybauer MO, Maybauer DM, Enkhbaatar P, et al. The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis. Crit Care Med 2014; 42:e525-e533.
35. Poelstra K, Bakker WW, Klok PA, et al. A physiologic function for alkaline phosphatase: endotoxin detoxification. Lab Invest 1997; 76:319-327.
36. Kapojos JJ, Poelstra K, Borghuis T, et al. Induction of glomerular alkaline phosphatase after challenge with lipopolysaccharide. Int J Exp Pathol 2003; 84:135-144.
37. Su F, Brands R, Wang Z, et al. Beneficial effects of alkaline phosphatase in septic shock. Crit Care Med 2006; 34:2182-2187.
38. Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med 2009; 37:417-423; e1.
39. Pickkers P, Heemskerk S, Schouten J, et al. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized doubleblind placebo-controlled trial. Crit Care 2012; 16:R14.
40. Yoo CH, Yeom JH, Heo JJ, et al. Interferon beta protects against lethal endotoxic and septic shock through SIRT1 upregulation. Sci Rep 2014; 4:4220.
41. Bellingan G, Maksimow M, Howell DC, et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med 2014; 2:98-107
42. Payen D, Mateo J, Cavaillon JM, et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009; 37:803-810.
43. Bellomo R, Cass A, Cole L, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361:1627-1638.
44. Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301:2445-2452.
45. Vincent JL. Sepsis: clearing the blood in sepsis. Nat Rev Nephrol 2009; 5:559-560.
46. Klein DJ, Foster D, Schorr CA, et al. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials 2014; 15:218.
47. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013; 13:862-874.
48. Leentjens J, Kox M, van der Hoeven JG, et al. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change Am J Respir Crit Care Med 2013; 187:1287-1293.
49. Bo L, Wang F, Zhu J, et al. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care 2011; 15:R58.
50. Hutchins NA, Unsinger J, Hotchkiss RS, et al. The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med 2014; 20:224-233.
51. Preiser JC, van Zanten AR, Berger MM, et al. Metabolic and nutritional support of critically ill patients: consensus and controversies. Crit Care 2015; 19:737.
52. Alhazzani W, Jacobi J, Sindi A, et al. The effect of selenium therapy on mortality in patients with sepsis syndrome: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med 2013; 41:1555-1564.
53. Launey Y, Nesseler N, Malledant Y, et al. Clinical review: fever in septic ICU patients-friend or foe Crit Care 2011; 15:222.